As stated in our Code of Conduct, Actelion Pharmaceuticals Deutschland GmbHis committed to complying with all applicable us laws and regulations and adhering to the highest ethical standards in our marketing, promotional, educational and research activities. A Comprehensive Compliance Program ("CCP") has been established by Actelion Pharmaceuticals Deutschland GmbHin accordance with California Health and Safety Codes §§ 119400 – 119402. Actelion Pharmaceuticals Deutschland GmbH, to the best of its knowledge and based on its good faith understanding of the statutory requirements, affirms that it is in compliance with this CCP and the referenced statutory requirements.
As the April 2003 Compliance Program Guidance for Pharmaceutical Manufacturers published by the us Department of Health and Human Services, Office of Inspector General (“OIG Guidance”) acknowledges that even with an effective CCP in place, the possibility that an individual employee engaging in conduct that can be considered improper or unethical cannot be completely eliminated. Actelion Pharmaceuticals Deutschland GmbH’s CCP was developed with the goal of preventing and detecting such improper conduct.
The Declaration became effective January 6, 2025, for the period January 1, 2025 to December 31, 2025. The CCP is a fluid and ever-changing program that is designed to meet the evolving regulatory and legislative climate. This program will be assessed on an annual basis.
A copy of this Declaration can be obtained by calling the toll-free number 1-866-246-8245 Ext. 8781 or from www.actelionpharmaceuticals.de .